Trial Profile
Malutiple-institutional observational surveillance of Pembrolizumab as a first line treatment for non-small cell lung cancer
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 26 May 2021
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Adenocarcinoma; Bone metastases; Non-small cell lung cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms HOPE-001
- 01 Apr 2021 Results (n=88) published in the BMC Cancer
- 30 Nov 2019 Results assessing association between metastatic sites and treatment outcomes of first line Pembrolizumab for patients with NSCLC were published in the Investigational New Drugs
- 07 Aug 2019 Status changed from recruiting to completed according to results published in the Investigational New Drugs.